On June 26, 2019, Achaogen (AKAO) announced mixed news to its anxious investors - the company's lead drug candidate, the antibiotic Zemdri (plazomicin), had been approved for the treatment of complicated urinary tract infections (cUTI), but had received a CRL for its potential indication for the treatment of bloodstream infections (BSIs). Despite the fact that Achaogen, with Zemdri's approval, has finally become a commercial-stage company, investors have been quite bearish on the stock since: the stock price has dropped from $12.02 on June 25, 2018 (the day before the Zemdri CRL/approval announcement) to $1.47 on